How to differentiate the B.1.1.7 variant from COVID-19 in hospitalized patients?

Yıl 2022, Cilt: 8 Sayı: 5, 629 - 635, 04.09.2022

İbrahim Koç , Yusuf Taha Gullu

https://doi.org/10.18621/eurj.1067946

Öz

Objectives: Little is known about COVID-19 and less about the B.1.1.7. There is a need for clinical information and tests to help doctors deal with the pandemic. This study aimed to investigate clinical and laboratory differences between hospitalized non-variant COVID-19 and the B.1.1.7 variant.

Methods: Data of 173 hospitalized non-variant COVID-19 and 176 B.1.1.7 variants were retrospectively investigated. D-dimer monocyte ratio (DMR) and ferritin monocyte ratio (FMR) values were calculated by dividing D-dimer and ferritin levels to monocyte count, respectively. Monocyte eosinophil ratio (MER) was obtained by dividing monocyte count by eosinophil levels.

Results: Clinical stay, intensive care unit (ICU) stay, and severe disease rates were found to be higher in the non-variant COVID-19. Eosinophil and basophil levels remained lower, whereas ferritin, FMR, and MER were more elevated in the same group. On ROC analysis, areas under the curve (AUC) of ferritin and FMR were found as 0.7 (p = 0.001) and 0.75 (p = 0.001), respectively.

Conclusions: The present study revealed that the B.1.1.7 variant had milder clinical manifestations, shorter clinic and ICU stay, and less severe disease rates than the non-variant COVID-19. Higher levels of ferritin, FMR, and MER may indicate the B.1.1.7 variant.

Anahtar Kelimeler

The B.1.1.7, variant, COVID-19, monocyte eosinophil ratio, eosinophils

Kaynakça

• 1. Wise J. Covid-19: New coronavirus variant is identified in UK. BMJ 2020;371:m4857.
• 2. Chen C, Nadeau SA, Topolsky I, Manceau M, Huisman JS, Jablonski KP, et al. Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland. Epidemics 2021;37:100480.
• 3. Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol 2013;88:218-30.
• 4. Gisondi P, Geat D, Lippi G, Montagnana M, Girolomoni G. Increased red blood cell distribution width in patients with plaque psoriasis. J Med Biochem 2021;40:199-201.
• 5. Lorente L, Martin MM, Argueso M, Sole-Violan J, Perez A, Marcos YRJA, et al. Association between red blood cell distribution width and mortality of COVID-19 patients. Anaesth Crit Care Pain Med 2021;40:100777.
• 6. Funk T, Pharris A, Spiteri G, Bundle N, Melidou A, Carr M, et al. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021. Euro Surveill 2021;26:2100348.
• 7. Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. J Infect Dis 2020;221:1762-9.
• 8. Gomez-Rial J, Curras-Tuala MJ, Rivero-Calle I, Gomez-Carballa A, Cebey-Lopez M, Rodriguez-Tenreiro C, et al. Increased serum levels of sCD14 and sCD163 indicate a preponderant role for monocytes in COVID-19 immunopathology. Front Immunol 2020;11:560381.
• 9. Xie G, Ding F, Han L, Yin D, Lu H, Zhang M. The role of peripheral blood eosinophil counts in COVID-19 patients. Allergy 2021;76:471-82.
• 10. Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020;75:1730-41.
• 11. Song Y, Ge Z, Cui S, Tian D, Wan G, Zhu S, et al. COVID-19 cases from the first local outbreak of the SARS-CoV-2 B.1.1.7 variant in China may present more serious clinical features: a prospective, comparative cohort study. Microbiol Spectr 2021;9:e0027321.
• 12. Veneti L, Seppala E, Larsdatter Storm M, Valcarcel Salamanca B, Alnes Buanes E, Aasand N, et al. Increased risk of hospitalisation and intensive care admission associated with reported cases of SARS-CoV-2 variants B.1.1.7 and B.1.351 in Norway, December 2020 -May 2021. PLoS One 2021;16:e0258513.
• 13. Davies NG, Jarvis CI, Group CC-W, Edmunds WJ, Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature 2021;593:270-74.
• 14. Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis. BMJ 2021;373:n1412.
• 15. Seyit M, Avci E, Nar R, Senol H, Yilmaz A, Ozen M, et al. Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19. Am J Emerg Med 2021;40:110-4.
• 16. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol 2020;84:106504.